Mintz Life Sciences Deal Activity (October – December 2020)

Mergers & Acquisitions

Represented Neurotrope, Inc. in its reverse merger with Metuchen Pharmaceuticals, LLC to form Petros Pharmaceuticals (December 2020)
- Simultaneously represented Neurotrope in the spin-off of substantially all of Neurotrope's existing assets, operations and liabilities, except for certain cash retained in accordance with the terms of the Merger Agreement, into a separately traded public company
Represented F-Star Therapeutics in its reverse merger with Spring Bank Pharmaceuticals (November 2020)
Represented Athenen Therapeutics in its merger with Eliem Therapeutics (October 2020)

Venture Capital

Represented Matrix Capital Management in its $15M investment in AltPep Corporation (December 2020)
Represented Antharis Therapeutics, Inc. in its $5.2M Series Seed financing led by Bionext Ltd. (December 2020)
Represented DxLab Inc. in its $4M Series Seed Preferred Stock financing led by Neoteny and E14 (December 2020)
Represented Avilar Therapeutics, Inc. in its $60M Series Seed financing (December 2020)
Represented Hopewell Therapeutics in its $500K Convertible Note financing (December 2020)
Represented NanoView Biosciences in its $6M extension of its Series B financing from a mix of existing and new investors (December 2020)
Represented PanTher Therapeutics, Inc. in its $1M extension of its Series A financing led by Angel Physicians Fund, LLC and Sayan Bioventure IV, LLC (November 2020)
Represented Endotronix, Inc. in its $15M extension of its Series D financing, bringing the total for the round to $70M (November 2020)
Represented DoubleRainbow Biosciences in its $30M Series B financing led by Gaorong Capital (October 2020)

Capital Markets

Represented the issuer:

Represented ImmunoGen, Inc. in its $150M at-the-market offering with Jefferies LLC acting as sales agent (December 2020)
Represented SELLAS Life Sciences Group, Inc. in its $16.2M registered direct offering with Maxim Group LLC acting as the placement agent (December 2020)
Represented Cyclacel Pharmaceuticals, Inc. in its $7M registered direct offering and concurrent private placement (December 2020)
Represented Fulgent Genetics in its $175M at-the-market offering with Piper Sandler & Co., BTIG, LLC and Oppenheimer & Co. Inc. acting as sales agents (November 2020)
Represented DermTech, Inc. in its $50M at-the-market offering with Cowen and Company LLC acting as sales agent (November 2020)
Represented Evofem Biosciences, Inc. in its $25M Convertible Note transaction with Adjuvant Capital (October 2020)

Represented the underwriters:

Represented the underwriters in the $147M public offering of Curis, Inc. underwritten by H.C. Wainwright & Co., LLC, Laidlaw & Company (UK) Ltd., Cantor Fitzgerald & Co. and JonesTrading Institutional Services, LLC (December 2020)
Represented the underwriters in the $3.2M Regulation A initial public offering of Scopus BioPharma Inc. underwritten by The Benchmark Company, LLC and Joseph Gunnar & Co., LLC (December 2020)
Represented the underwriters in the $80M initial public offering of Galecto, Inc. underwritten by BofA Securities, SVB Leerink, Credit Suisse and Kempen & Co. (November 2020)
Represented the underwriters in the $40M public offering of Forte Biosciences, Inc. underwritten by Truist Securities, Inc., Ladenburg Thalmann & Co. Inc., Chardan Capital Markets, LLC and Brookline Capital Markets, LLC (October 2020)
Represented the underwriters in the $9.5M public offering of Isoray, Inc. underwritten by Oppenheimer & Co. Inc. (October 2020)
Represented the underwriters in the $190M initial public offering of Praxis Precision Medicines, Inc. underwritten by Cowen, Evercore ISI, Piper Sandler, Wedbush PacGrow and Blackstone Capital Markets (October 2020)
Represented the underwriters in the $6.6M public offering of Artelo Biosciences, Inc. underwritten by Ladenburg Thalmann & Co. Inc. (October 2020)

Represented the sales agent / placement agent:

Represented the sales agent in a $50M at-the-market offering of Rezolute, Inc. with Oppenheimer & Co. Inc. acting as sales agent (December 2020)
Represented the sales agents in a $25M at-the-market offering of VolitionRx Limited with Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. acting as sales agents (November 2020)